Literature DB >> 8931792

The feasibility of HIV-1 vaccine efficacy trials among gay/bisexual men in New York City: Project ACHIEVE. AIDS Community Health Initiative Enroute to the Vaccine EFfort.

B A Koblin1, P E Taylor, S Avrett, C E Stevens.   

Abstract

OBJECTIVE: Candidate populations for HIV-1 vaccine efficacy trials need to be at high risk of infection, adhere to study protocols and be willing to participate. The goal of Project ACHIEVE is to collect baseline data needed in order to prepare for vaccine efficacy trials among gay/bisexual men in New York City. DESIGN AND METHODS: HIV-1 antibody-negative men were recruited into a cohort study with follow-up visits every 3 months (n = 622). Frequency of high-risk behaviors and incidence of HIV-1 seroconversion were measured.
RESULTS: Of 544 men reporting having had at least one partner in the previous 3 months who was HIV-1 antibody-positive or of unknown status at baseline, 49% reported receptive anal sex encounters. Thirty-two per cent of these men reported the highest risk behavior, unprotected receptive anal sex. The follow-up rate at 12 months was 81%. The incidence rate of infection was 2.9 per 100 person-years (95% confidence interval: 1.7, 4.9). During follow-up, declines were observed in the proportion of men with an HIV-1 antibody-positive partner and the proportion reporting unprotected receptive or insertive anal sex. HIV-1 infection rates declined from 4.3 per 100 person-years in the first 6 months to 1.6 per 100 person-years by the 12-month visit.
CONCLUSIONS: Gay/bisexual men in New York City are still placing themselves at risk of HIV-1 infection and may be a suitable population for future vaccine trials. Continued follow-up is needed to further define the incidence over time, especially for the period after the initial 3 to 6 months when vaccines are most likely to be effective. Immediate prevention efforts need to target this population more effectively.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8931792     DOI: 10.1097/00002030-199611000-00015

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  10 in total

1.  HIV in the United States at the turn of the century: an epidemic in transition.

Authors:  J M Karon; P L Fleming; R W Steketee; K M De Cock
Journal:  Am J Public Health       Date:  2001-07       Impact factor: 9.308

2.  Anal sex and HIV transmission in women.

Authors:  S S Karim; G Ramjee
Journal:  Am J Public Health       Date:  1998-08       Impact factor: 9.308

Review 3.  Socio-behaviour challenges to phase III HIV vaccine trials in Sub-Saharan Africa.

Authors:  Joalida Smit; Keren Middelkoop; Landon Myer; Graham Lindegger; Leslie Swartz; Soraya Seedat; Tim Tucker; Robin Wood; Linda-Gail Bekker; Dan J Stein
Journal:  Afr Health Sci       Date:  2005-09       Impact factor: 0.927

4.  Willingness to participate in HIV-1 vaccine trials among young Thai men.

Authors:  R A Jenkins; K Torugsa; L E Markowitz; C J Mason; V Jamroentana; A E Brown; S Nitayaphan
Journal:  Sex Transm Infect       Date:  2000-10       Impact factor: 3.519

Review 5.  Effect of race/ethnicity on participation in HIV vaccine trials and comparison to other trials of biomedical prevention.

Authors:  Shayesta Dhalla; Gary Poole
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Recruitment of men who have sex with men for large HIV intervention trials: analysis of the EXPLORE Study recruitment effort.

Authors:  Patrick Barresi; Marla Husnik; Michael Camacho; Borris Powell; Reggie Gage; Darren LeBlanc; Paul Verano; Margaret Chesney; Beryl Koblin
Journal:  AIDS Educ Prev       Date:  2010-02

7.  Recruitment of urban US women at risk for HIV infection and willingness to participate in future HIV vaccine trials.

Authors:  Barbara Metch; Ian Frank; Richard Novak; Edith Swann; David Metzger; Cecilia Morgan; Debbie Lucy; Debora Dunbar; Parrie Graham; Tamra Madenwald; Gina Escamilia; Beryl Koblin
Journal:  AIDS Behav       Date:  2013-02

8.  Feasibility of identifying a cohort of US women at high risk for HIV infection for HIV vaccine efficacy trials: longitudinal results of HVTN 906.

Authors:  Beryl A Koblin; Barbara Metch; Richard M Novak; Cecilia Morgan; Debbie Lucy; Debora Dunbar; Parrie Graham; Edith Swann; Tamra Madenwald; Gina Escamilia; Ian Frank
Journal:  J Acquir Immune Defic Syndr       Date:  2013-06-01       Impact factor: 3.731

9.  Anal sex role segregation and versatility among men who have sex with men: EXPLORE Study.

Authors:  Hong-Van Tieu; Xin Li; Deborah Donnell; Eric Vittinghoff; Susan Buchbinder; Zachary G Parente; Beryl Koblin
Journal:  J Acquir Immune Defic Syndr       Date:  2013-09-01       Impact factor: 3.731

Review 10.  HIV and hepatitis B and C incidence rates in US correctional populations and high risk groups: a systematic review and meta-analysis.

Authors:  Ethan Gough; Mirjam C Kempf; Laura Graham; Marvin Manzanero; Edward W Hook; Al Bartolucci; Eric Chamot
Journal:  BMC Public Health       Date:  2010-12-21       Impact factor: 3.295

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.